Diagnosis of cure in cushing's syndrome: Lessons from long-term follow-up

M. J. Barahona, E. Resmini, N. Sucunza, S. M. Webb

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

13 Cites (Scopus)

Resum

It is generally assumed that endocrine 'cure' of hypercortisolism after successful treatment for Cushing's syndrome (CS) is associated with reversal of increased morbidity and mortality, typical of the active disease. However, recent data do not support this idea; increased cardiovascular risk is still present 5 years after endocrine cure, and health-related quality of life (HRQoL), although improved when compared to the active phase of hypercortisolism, is still impaired when compared to normal population. Abnormal body composition typical of hypercortisolism (i.e., increased total and trunk fat, reduced bone mass and lean body mass) is not completely normalized, even years after controlling hypercortisolism. Thus, control of hypercortisolism in CS does not normalize HRQoL, long-term cardiovascular risk and morbidity, body composition nor some metabolic parameters. Whether the same occurs in patients exposed to pharmacological doses of exogenous glucocorticoids, and whether the body composition abnormalities associated with the exposure to exogenous glucocorticoids are reversible or not, are worth considering. Copyright © 2010 S. Karger AG, Basel.
Idioma originalAnglès
Pàgines (de-a)152-157
RevistaFrontiers of Hormone Research
Volum38
DOIs
Estat de la publicacióPublicada - 20 d’ag. 2010

Fingerprint

Navegar pels temes de recerca de 'Diagnosis of cure in cushing's syndrome: Lessons from long-term follow-up'. Junts formen un fingerprint únic.

Com citar-ho